DBV712 250 mcg
Sponsors
DBV Technologies
Conditions
AllergyPeanut Allergy
Phase 3
Follow-up of the EPITOPE Study to Evaluate Long-term Efficacy and Safety of DBV712 in Young Children
CompletedNCT03859700
Start: 2018-12-06End: 2025-05-13Updated: 2025-06-06
Safety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers)
Active, not recruitingNCT07003919
Start: 2025-06-24End: 2028-05-01Target: 480Updated: 2026-07-22